SCHEMBL6369449

SCHEMBL6369449

COC(=O)c1ccc(NC(=O)c2cc3cc(F)ccc3[nH]2)c2c1OCCCO2

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.52
ALDH1A1 P00352 4/20 0.52
RXFP1 Q9HBX9 3/20 0.52
NPSR1 Q6W5P4 1/20 0.52
KMT2A Q03164 4/20 0.49
MEN1 O00255 3/20 0.49
MLLT1 Q03111 1/20 0.46
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
APP P05067 2/20 0.43
FLT3 P36888 1/20 0.43
PDPK1 O15530 1/20 0.41
LMNA P02545 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
NFKB1 P19838 1/20 0.41
APEX1 P27695 1/20 0.41
CYP2C19 P33261 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6374614 0.89 KDM4E (0.49) KDM4EALDH1A1RXFP1NPSR1KMT2A
SCHEMBL6369837 0.89 NHERF1 (0.51) KDM4EALDH1A1RXFP1KMT2AMEN1
SCHEMBL6369114 0.87 NPC1 (0.48) KDM4EALDH1A1NPC1RAB9ALMNA
SCHEMBL6376602 0.77 NHERF1 (0.62) RXFP1KMT2AMEN1
SCHEMBL6369287 0.76 NPC1 (0.52) KDM4EALDH1A1NPC1RAB9ALMNA
SCHEMBL856326 0.73 TDP1 (0.43) KDM4EALDH1A1NPSR1KMT2AMEN1
SCHEMBL2731044 0.72 KDM4E (0.66) KDM4EALDH1A1RXFP1NPSR1MLLT1
SCHEMBL6368672 0.72 PYGL (0.51) KDM4ERXFP1KMT2AMEN1NPC1
SCHEMBL24196808 0.69 FLT3 (0.60) KDM4EALDH1A1RXFP1NPSR1KMT2A
SCHEMBL13761503 0.69 MLLT1 (0.61) KDM4EALDH1A1RXFP1NPSR1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050020661-A1 Substituted 1H-indole-2- carboxamides and 6H-thieno(2,3-b)pyrrole-5-carboxamides useful for inhibiting glycogen phosphorylase in a mammal GAMMILL RONALD B (US) 2005-01-27 US disclosed
US-6821977-B2 SUBSTITUTED 1H-(INDOLE-2- CARBOXAMIDES AND 6H-THIENO(2,3-B)PYRROLE-5-CARBOXAMIDES USEFUL FOR INHIBITING GLYCOGEN PHOSPHORYLASE IN A MAMMAL PFIZER, INC. 2004-11-23 US disclosed
US-20030199553-A1 Antidiabetic agents GAMMILL RONALD B (US) 2003-10-23 US disclosed
EP-1340500-A1 Antidiabetic agents Pfizer Products Inc. (US) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199553-A1 Antidiabetic agents GPR119, IRS1, INSR KDM4E 4333/4885ALDH1A1 1021/4885RXFP1 334/4885
US-20050020661-A1 Substituted 1H-indole-2- carboxamides and 6H-thieno(2,3-b)pyrrole-5-carboxamides useful for inhibiting glycogen phosphorylase in a mammal PYGM, PYGL, IRS1 KDM4E 1273/4885ALDH1A1 2263/4885RXFP1 866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.